Last Updated:
Searching
Create account to add to watchlist!

Compute Health Acquisition Corp. - CPUH

  • Commons

    $9.80

    -0.20%

    CPUH Vol: 552.0K

  • Warrants

    $1.15

    +0.88%

    CPUH+ Vol: 141.8K

  • Units

    $10.04

    -0.10%

    CPUH= Vol: 332.6K

Average: 0
Rating Count: 0
You Rated: Not rated

Please log in to rate.

SPAC Stats

Market Cap: 845.2M
Average Volume: 213.0K
52W Range: $9.50 - $10.70
Weekly %: -0.10%
Monthly %: +0.10%
Inst Owners: 29

Info

Target: Searching
Days Since IPO: 297
Unit composition:
Each unit has an offering price of $10.00 and consists of one share of our Class A common stock and one-quarter of one redeemable warrant
Trust Size: 75000000.0M

🕵Stocktwit Mentions

Kornie7 posted at 2021-11-26T18:17:21Z

$CPUH nice close warrants green!!!!

BlingCrosby posted at 2021-11-26T17:55:11Z

$CPUH Warrant volume. This is my requisite “someone knows something” comment

T8skmod posted at 2021-11-26T07:56:18Z

$CPUH Twits Stats Today's Change 38% + 🚀 https://t8sk.com/CPUH

cajunman posted at 2021-11-25T01:10:00Z

$CPUH intuitive robotics isrd is a surgical robotics robotics company, their stock is over 300 and has split a few times already. If we plan to merge with a surgical robot company this could be huge. 👍

cajunman posted at 2021-11-24T20:52:16Z

$CPUH been watching this one for a while gotta feeling they will surprise everyone soon. 👍

Tickstocks posted at 2021-11-24T05:28:06Z

$CPUH Twits Stats Today's Change 38% + 🚀 https://t8sk.com/CPUH

Arnold_Stockzennegger posted at 2021-11-23T21:09:12Z

$CPUH nice volume on the warrants makes me bust out my W shirt

BlingCrosby posted at 2021-11-23T21:00:51Z

$CPUH Nice warrant close

BlingCrosby posted at 2021-11-23T20:26:48Z

$CPUH Y’all chase these warrants and send em over 1.2 real quick

BlingCrosby posted at 2021-11-23T20:18:03Z

$CPUH 😎

Kornie7 posted at 2021-11-23T20:14:33Z

$CPUH our time is near!!!!

Kornie7 posted at 2021-11-23T19:55:59Z

$CPUH warrants 10x

BullVBear posted at 2021-11-23T17:59:02Z

$CPUH https://www.google.com/amp/s/uaenews247.com/2021/07/06/saudi-german-hospital-dubai-performed-the-first-cmr-versius-robotic-surgery-in-the-uae/amp/

BullVBear posted at 2021-11-23T17:36:15Z

$CPUH Tempus considering IPO. We could technically buy into that IPO with our spac, but I’m actually hoping for CMR robotics.

Faran786 posted at 2021-11-23T16:38:11Z

$CPUH WE MISSED THIS! Alswailem is the CIO at the biggest hospital in Saudi. My friend has said all the kings and royalty attend that hospital. What's more is Osama focuses specifically on research and IT Healthcare. This is why the Saudi PIF investd.. cards are clicking...

Faran786 posted at 2021-11-23T16:11:40Z

$CPUH filled. Thank you. Now we wait😋

Arnold_Stockzennegger posted at 2021-11-23T15:36:10Z

$HAAC warrants back in buy range $CPUH $LUXA

Faran786 posted at 2021-11-23T03:42:35Z

$CPUH I’m still waiting to fill my 26k order I don’t want to hit the ask and buy with a 1.30 avg. volume is soo slow. Any suggestions?

BlingCrosby posted at 2021-11-22T15:00:37Z

$CPUH Feel like I’m talking to myself on this board, but there’s some warrant volume here. 🤷🏻‍♂️

Last10K posted at 2021-11-22T11:10:44Z

$CPUH just filed with the SEC a Interim Review and a Financial Exhibit https://last10k.com/sec-filings/cpuh/0001213900-21-060941.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=8K&utm_term=cpuh

risenhoover posted at 2021-11-22T11:02:54Z

$CPUH / Compute Health Acquisition files form 8-K - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 19, 2021 (November 15, 2 https://fintel.io/sf/us/cpuh?utm_source=stocktwits.com&utm_medium=Referral&utm_campaign=filing

Quantisnow posted at 2021-11-22T11:02:45Z

$CPUH 📜 Compute Health Acquisition Corp. filed SEC Form 8-K: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Financial Statements and Exhibits https://quantisnow.com/insight/2038559?s=s 45 seconds delayed.

BullVBear posted at 2021-11-19T21:32:05Z

$CPUH we will wake up with these warrants up 100%+ one day. And when that happens we just hold for 10x.

Last10K posted at 2021-11-19T11:08:07Z

$CPUH just filed a 10-Q Quarterly Report with 40 sections and 4 exhibits. Access them all or just read their earnings: https://last10k.com/sec-filings/cpuh/0001213900-21-060690.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=10KQ2040F&utm_term=cpuh

Newsfilter posted at 2021-11-19T11:06:59Z

$CPUH Form 10-Q (quarterly report [sections 13 or 15(d)]) filed with the SEC https://newsfilter.io/a/b61c9f9ff6f9584b89fe2874f7bb6990

risenhoover posted at 2021-11-19T11:05:55Z

$CPUH / Compute Health Acquisition files form 10-Q https://fintel.io/sf/us/cpuh?utm_source=stocktwits.com&utm_medium=Referral&utm_campaign=filing

Quantisnow posted at 2021-11-19T11:05:43Z

$CPUH 📜 SEC Form 10-Q filed by Compute Health Acquisition Corp. https://quantisnow.com/insight/2033299?s=s This and other insights appear 45 seconds early at 💪 https://quantisnow.com/feed 💪

BullVBear posted at 2021-11-19T01:04:14Z

$CPUH https://open.spotify.com/episode/3yam2eDSbET9NUuiYVuGH8?si=co2ru-slSI6MpEYdE3WUvg

Kornie7 posted at 2021-11-18T18:46:28Z

$CPUH please be a top quantum computing

Kornie7 posted at 2021-11-18T18:13:32Z

$PIPP $CPUH the warrant action is interesting

Management

Officers and Directors,” “Management — Conflicts of Interest” and “Certain Relationships and Related Party Transactions.” Our officers, directors, security holders and their respective affiliates may have competitive pecuniary interests that conflict with our interests. We have not adopted a policy that expressly prohibits our directors, officers, security holders or affiliates from having a direct or indirect pecuniary or financial interest in any investment to be acquired or disposed of by us or in any transaction to which we are a party or have an interest. In fact we may enter into a business combination with a target business that is affiliated with our initial stockholders, directors or officers, or any of their affiliates although we do not currently intend to do so. We do not have a policy that expressly prohibits any such persons from engaging for their own account in business activities of the types conducted by us. Accordingly, such persons or entities may have a conflict between their interests and ours. 68 Table of Contents Despite our agreement that, in the event we seek to complete our initial business combination with a company business that is affiliated with our initial stockholders, officers or directors, or any of their affiliates, we, or a committee of independent directors, will obtain an opinion from an independent investment banking firm that is a member of FINRA or another independent entity that commonly renders valuation opinions that our initial business combination is fair to us from a financial point of view, potential conflicts of interest still may exist. As a result, the terms of the business combination may not be as advantageous to our company and our public stockholders as they would be absent any conflicts of interest. The personal and financial interests of our directors and officers may influence their motivation in timely identifying and selecting a target business and completing a business combination. Consequently, our directors’ and officers’ discretion in identifying and selecting a suitable target business may result in a conflict of interest when determining whether the terms, conditions and timing of a particular business combination are appropriate and in our stockholders’ best interest. If this were the case, it would be a breach of their fiduciary duties to us as a matter of Delaware law and we or our stockholders might have a claim against such individuals for infringing on our stockholders’ rights. However, we might not ultimately be successful in any claim we may make against them for such reason. Since our sponsor, officers and directors will lose their entire investment in us if our business combination is not completed, a conflict of interest may arise in determining whether a particular target business is appropriate for our initial business combination. Our initial stockholders acquired the 18,750,000 founder shares in exchange for a capital contribution of $25,000. Prior to the initial investment in the company of $25,000, we had no assets, tangible or intangible. The number of founder shares issued was determined based on the expectation that such founder shares would represent 20% of the outstanding shares after this offering. The founder shares will be worthless if we do not complete an initial business combination. In addition, our sponsor has committed to purchase an aggregate of 11,333,333 (or 12,833,333 if the underwriters’ over-allotment option is exercised in full) private placement warrants, each exercisable for one share of our Class A common stock at $11.50 per share, subject to adjustment, for a purchase price of $17,000,000 (or $19,250,000 if the underwriters’ over-allotment option is exercised in full), or $1.50 per warrant, that will also be worthless if we do not complete our initial business combination within the allocated time period. In addition, we may obtain loans from our initial stockholders, officers, directors, or their affiliates. The personal and financial interests of our officers and directors may influence their motivation in identifying and selecting a target business combination, completing an initial business combination and influencing the operation of the business following the initial business combination. This risk may become more acute as the deadline for completing our initial business combination nears. We are an emerging growth company and a smaller reporting company within the meaning of the Securities Act, and if we take advantage of certain exemptions from disclosure requirements available to emerging growth companies and smaller reporting companies, this could make our securities less attractive to investors and may make it more difficult to compare our performance with other public companies. We are an “emerging growth company” within the meaning of the Securities Act, as modified by the JOBS Act, and we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. As a result, our stockholders may not have access to certain information they may deem important. We could be an emerging growth company for up to five years, although circumstances could cause us to lose that status earlier, including if the market value of our common stock held by non-affiliates exceeds $700 million as of the end of any second quarter of a fiscal year, in which case we would no longer be an emerging growth company as of the end of such fiscal year. We cannot predict whether investors will find our securities less attractive because we will rely on these exemptions. If some investors find our securities less attractive as a result of our reliance on these exemptions, the trading prices of our securities may be lower than they otherwise would be, there may be a less active trading market for our securities and the trading prices of our securities may be more volatile. 69 Table of Contents Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. We have elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of our financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Additionally, we are a “smaller reporting company” as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which (1) the market value of our common stock held by non-affiliates exceeds $250 million as of the end of that year’s second fiscal quarter, or (2) our annual revenues exceeded $100 million during such completed fiscal year and the market value of our common stock held by non-affiliates exceeds $700 million as of the end of that year’s second fiscal quarter. To the extent we take advantage of such reduced disclosure obligations, it may also make comparison of our financial statements with other public companies difficult or impossible. Provisions in our certificate of incorporation and Delaware law may inhibit a takeover of us, which could limit the price investors might be willing to pay in the future for our Class A common stock and could entrench management. Our certificate of incorporation will contain provisions that may discourage unsolicited takeover proposals that stockholders may consider to be in their best interests. These provisions include a staggered board of directors and the ability of the board of directors to designate the terms of and issue new series of preferred shares and the fact that prior to the completion of our initial business combination only holders of our shares of Class B common stock, which are held by our initial stockholders, are entitled to vote on the election of directors and holders of a majority of the outstanding shares of our Class B common stock may remove members of our board of directors for any reason, each of which may make the removal of management more difficult and may discourage transactions that otherwise could involve payment of a premium over prevailing market prices for our securities. We are also subject to anti-takeover provisions under Delaware law, which could delay or prevent a change of control. Together these provisions may make the removal of management more difficult and may discourage transactions that otherwise could involve payment of a premium over prevailing market prices for our securities. Since only holders of our founder shares will have the right to vote on the appointment of directors, upon the listing of our shares on the NYSE, the NYSE may consider us to be a “controlled company” within the meaning of the NYSE rules and, as a result, we may qualify for exemptions from certain corporate governance requirements. After completion of this offering, only holders of our founder shares will have the right to vote on the appointment of directors. As a result, the NYSE may consider us to be a “controlled company” within the meaning of the NYSE corporate governance standards. Under the NYSE corporate governance standards, a company of which more than 50% of the voting power is held by an individual, group or another company is a “controlled company” and may elect not to comply with certain corporate governance requirements, including the requirements that: • we have a board that includes a majority of “independent directors,” as defined under the rules of the NYSE; 70 Table of Contents • we have a compensation committee of our board that is comprised entirely of independent directors with a written charter addressing the committee’s purpose and responsibilities; and • we have a nominating and corporate governance committee of our board that is comprised entirely of independent directors with a written charter addressing the committee’s purpose and responsibilities. We do not intend to utilize these exemptions and intend to comply with the corporate governance requirements of the NYSE, subject to applicable phase-in rules. However, if we determine in the future to utilize some or all of these exemptions, you will not have the same protections afforded to shareholders of companies that are subject to all of the NYSE corporate governance requirements. Risks Associated with Acquiring and Operating a Business in Foreign Countries We may reincorporate in another jurisdiction in connection with our initial business combination and such reincorporation may result in taxes imposed on shareholders. We may effect a business combination with a target company in another jurisdiction, reincorporate in the jurisdiction in which the target company or business is located, or reincorporate in another jurisdiction. Such transactions may result in tax liability for a shareholder in the jurisdiction in which the shareholder is a tax resident (or in which its members are resident if it is a tax transparent entity), in which the target company is located, or in which we reincorporate. We do not intend to make any cash distributions to shareholders to pay such taxes. Shareholders may be subject to withholding taxes or other taxes with respect to their ownership of us after the reincorporation. If we complete our initial business combination with a company with operations or opportunities outside of the United States, we would be subject to a variety of additional risks that may negatively impact our operations. If we complete our initial business combination with a company with operations or opportunities outside of the United States, we would be subject to any special considerations or risks associated with companies operating in an international setting, including any of the following: • higher costs and difficulties inherent in managing cross-border business operations and complying with different commercial and legal requirements of overseas markets; • rules and regulations regarding currency redemption; • complex withholding taxes; • laws governing the manner in which future business combinations may be effected; • exchange listing and/or delisting requirements; • tariffs and trade barriers; • regulations related to customs and import/export matters; • local or regional economic policies and market conditions; • unexpected changes in regulatory requirements; • challenges in managing and staffing international operations; • longer payment cycles and challenges in collecting accounts receivable; • tax issues, such as tax law changes and variations in tax laws as compared to the United States; • currency fluctuations and exchange controls; • rates of inflation; 71 Table of Contents • cultural and language differences; • employment regulations; • underdeveloped or unpredictable legal or regulatory systems; • corruption; • protection of intellectual property; • social unrest, crime, strikes, riots and civil disturbances; • regime changes and political upheaval; • crime, strikes, riots, civil disturbances, terrorist attacks, natural disasters and wars; • deterioration of political relations with the United States; and • government appropriations of assets. We may not be able to adequately address these additional risks. If we were unable to do so, our operations might suffer, which may adversely impact our results of operations and financial condition. Risks Relating to the Healthcare Industry There are risks related to the healthcare industry to which we may be subject. Business combinations with companies with operations in the healthcare industry entail special considerations and risks. If we are successful in completing a business combination with a target business with operations in the healthcare industry, we will be subject to, and possibly adversely affected by, the following risks, including but not limited to: • Competition could reduce profit margins. • Our inability to comply with governmental regulations affecting the healthcare industry could negatively affect our operations. • An inability to license or enforce intellectual property rights on which our business may depend. • The success of our planned business following consummation of our initial business combination may depend on maintaining a well-secured business and technology infrastructure. • If we are required to obtain governmental approval of our products, the production of our products could be delayed and we could be required to engage in a lengthy and expensive approval process that may not ultimately be successful. • Continuing government and private efforts to contain healthcare costs, including through the implementation of legal and regulatory changes, may reduce our future revenue and our profitability following such business combination. • Changes in the healthcare related wellness industry and markets for such products affecting our customers or retailing practices could negatively impact customer relationships and our results of operations. • The healthcare industry is susceptible to significant liability exposure. If liability claims are brought against us following a business combination, it could materially adversely affect our operations. • Dependence of our operations upon third-party suppliers, manufacturers or contractors whose failure to perform adequately could disrupt our business. 72 Table of Contents • The Affordable Care Act, possible changes to it or its repeal, and how it is implemented could negatively impact our business. • A disruption in supply could adversely impact our business. Any of the foregoing could have an adverse impact on our operations following a business combination. However, our efforts in identifying prospective target businesses will not be limited to the healthcare industry. Accordingly, if we acquire a target business in another industry, these risks will likely not affect us and we will be subject to other risks attendant with the specific industry in which we operate or target business which we acquire, none of which can be presently ascertained. General Risk Factors Changes in laws or regulations, or a failure to comply with any laws and regulations, may adversely affect our business, investments and results of operations. We are subject to laws and regulations enacted by national, regional and local governments. In particular, we will be required to comply with certain SEC and other legal requirements. Compliance with, and monitoring of, applicable laws and regulations may be difficult, time consuming and costly. Those laws and regulations and their interpretation and application may also change from time to time and those changes could have a material adverse effect on our business, investments and results of operations. In addition, a failure to comply with applicable laws or regulations, as interpreted and applied, could have a material adverse effect on our business, including our ability to negotiate and complete our initial business combination, and results of operations. Provisions in our amended and restated certificate of incorporation and Delaware law may have the effect of discouraging lawsuits against our directors and officers. Our amended and restated certificate of incorporation will require, unless we consent in writing to the selection of an alternative forum, that (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee to us or our stockholders, (iii) any action asserting a claim against us, our directors, officers or employees arising pursuant to any provision of the DGCL or our amended and restated certificate of incorporation or bylaws, or (iv) any action asserting a claim against us, our directors, officers or employees governed by the internal affairs doctrine may be brought only in the Court of Chancery in the State of Delaware, except any claim (A) as to which the Court of Chancery of the State of Delaware determines that there is an indispensable party not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten days

Holder Stats

1 0
% of Shares Held by All Insider 0.00%
% of Shares Held by Institutions 16.39%
% of Float Held by Institutions 16.39%
Number of Institutions Holding Shares 29

Institutional Holders

Reporting Date Hedge Fund Shares Held Market Value % of Portfolio Quarterly Change in Shares Ownership in Company
2021-11-17 Centiva Capital LP 608,075 $5,940,000 0.3% +0.4% 0.564%
2021-11-16 Schonfeld Strategic Advisors LLC 41,812 $410,000 0.0% +31.4% 0.039%
2021-11-16 Centiva Capital LP 608,075 $5,940,000 0.4% +0.4% 0.564%
2021-11-15 Polar Asset Management Partners Inc. 500,000 $4,890,000 0.0% -13.3% 0.464%
2021-11-15 Berkley W R Corp 85,407 $830,000 0.1% +40.7% 0.079%
2021-11-15 Omni Partners US LLC 60,480 $590,000 0.0% -4.3% 0.056%
2021-11-15 Penserra Capital Management LLC 21,721 $210,000 0.0% -18.5% 0.020%
2021-11-15 Dark Forest Capital Management LP 5,856 $57,000 0.0% 0 0.005%
2021-11-15 HighTower Advisors LLC 820,186 $8,020,000 0.0% +54.8% 0.761%
2021-11-12 Weiss Asset Management LP 1,788,797 $17,480,000 0.4% +2,670.0% 1.659%
2021-11-12 Wolverine Asset Management LLC 69,723 $680,000 0.0% -9.5% 0.065%
2021-11-12 Cohanzick Management LLC 8,210 $80,000 0.0% 0 0.008%
2021-11-12 Crestline Management LP 10,300 $100,000 0.0% 0 0.010%
2021-11-09 ATW Spac Management LLC 5,200 $51,000 0.0% 0 0.005%
2021-11-02 Raymond James Financial Services Advisors Inc. 14,461 $140,000 0.0% 0 0.013%
2021-10-25 Exos Asset Management LLC 12,189 $120,000 0.1% -61.4% 0.011%
2021-08-24 Flow Traders U.S. LLC 63,052 $620,000 0.0% 0 0.058%
2021-08-17 Beryl Capital Management LLC 658,928 $6,470,000 0.6% +490.2% 0.611%
2021-08-16 Whitebox Advisors LLC 64,600 $630,000 0.0% 0 0.060%
2021-08-16 Bank of America Corp DE 130,222 $1,280,000 0.0% +456.5% 0.121%
2021-08-16 Rivernorth Capital Management LLC 400,000 $3,930,000 0.2% 0 0.371%
2021-08-16 Schonfeld Strategic Advisors LLC 31,812 $310,000 0.0% 0 0.030%
2021-08-16 Polygon Management Ltd. 25,000 $250,000 0.0% 0 0.023%
2021-08-16 DLD Asset Management LP 96,000 $940,000 0.1% -68.0% 0.089%
2021-08-13 RP Investment Advisors LP 1,628,213 $15,990,000 2.1% 0 1.510%
2021-08-13 Qube Research & Technologies Ltd 64,012 $630,000 0.0% 0 0.059%
2021-08-12 Penserra Capital Management LLC 26,661 $260,000 0.0% 0 0.025%
2021-05-11 Poehling Capital Management LLC 89,160 $900,000 0.3% 0 0.357%
2021-05-10 Basso Capital Management L.P. 5,600 $55,000 0.0% 0 0.022%
2021-04-19 Boston Standard Wealth Management LLC 10,000 $100,000 0.0% 0 0.040%

SEC Filings

Form Type Form Description Filing Date Document Link
8-K CURRENT REPORT 2021-11-22 https://www.sec.gov/Archives/edgar/data/1828608/000121390021060941/ea151079-8k_compute.htm
10-Q QUARTERLY REPORT 2021-11-19 https://www.sec.gov/Archives/edgar/data/1828608/000121390021060690/f10q0921_computehealth.htm
NT 10-Q NOTIFICATION OF LATE FILING 2021-11-16 https://www.sec.gov/Archives/edgar/data/1828608/000121390021059760/ea150632-nt10q_computehealth.htm
10-Q QUARTERLY REPORT 2021-08-16 https://www.sec.gov/Archives/edgar/data/1828608/000121390021042599/f10q0621_computehealth.htm
10-Q QUARTERLY REPORT 2021-05-24 https://www.sec.gov/Archives/edgar/data/1828608/000121390021028795/f10q0321_computehealth.htm
NT 10-Q NOTIFICATION OF LATE FILING 2021-05-17 https://www.sec.gov/Archives/edgar/data/1828608/000121390021027055/ea141043-nt10q_computehealth.htm
8-K CURRENT REPORT 2021-04-12 https://www.sec.gov/Archives/edgar/data/1828608/000121390021021187/ea139395-8k_compute.htm
8-K CURRENT REPORT 2021-03-26 https://www.sec.gov/Archives/edgar/data/1828608/000121390021017999/ea138472-8k_computehealth.htm
SC 13G SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP 2021-02-18 https://www.sec.gov/Archives/edgar/data/1828608/000138713121002651/pif-sc13g_020921.htm
8-K CURRENT REPORT 2021-02-16 https://www.sec.gov/Archives/edgar/data/1828608/000121390021009606/ea135626-8k_computehealth.htm
8-K/A AMENDMENT NO. 1 TO FORM 8-K 2021-02-16 https://www.sec.gov/Archives/edgar/data/1828608/000121390021009585/ea135656-8ka1_compute.htm
8-K CURRENT REPORT 2021-02-09 https://www.sec.gov/Archives/edgar/data/1828608/000121390021007774/ea134809-8k_computehealth.htm
424B4 PROSPECTUS 2021-02-08 https://www.sec.gov/Archives/edgar/data/1828608/000121390021007315/f424b4_computehealth.htm
EFFECT 2021-02-04 https://www.sec.gov/Archives/edgar/data/1828608/999999999521000451/xslEFFECTX01/primary_doc.xml
3 2021-02-04 https://www.sec.gov/Archives/edgar/data/1828608/000121390021006927/xslF345X02/ownership.xml
3 2021-02-04 https://www.sec.gov/Archives/edgar/data/1828608/000121390021006925/xslF345X02/ownership.xml
3 2021-02-04 https://www.sec.gov/Archives/edgar/data/1828608/000121390021006923/xslF345X02/ownership.xml
3 2021-02-04 https://www.sec.gov/Archives/edgar/data/1828608/000121390021006921/xslF345X02/ownership.xml
3 2021-02-04 https://www.sec.gov/Archives/edgar/data/1828608/000121390021006920/xslF345X02/ownership.xml
CERT NYSE CERTIFICATION 2021-02-03 https://www.sec.gov/Archives/edgar/data/1828608/000087666121000168/CPUH020321.pdf
8-A12B FOR REGISTRATION OF CERTAIN CLASSES 2021-02-03 https://www.sec.gov/Archives/edgar/data/1828608/000121390021006382/ea134526-8a12b_computehealth.htm
S-1/A REGISTRATION STATEMENT 2021-01-29 https://www.sec.gov/Archives/edgar/data/1828608/000121390021005190/fs12021a1_computehealth.htm
S-1 REGISTRATION STATEMENT 2021-01-20 https://www.sec.gov/Archives/edgar/data/1828608/000121390021003054/fs12021_computehealth.htm
DRS 2020-11-20 https://www.sec.gov/Archives/edgar/data/1828608/000121390020038508/filename1.htm